1. Introduction

Biotechnology Procurement Governance Accountability refers to the legal and administrative framework through which governments, public research institutions, hospitals, universities, pharmaceutical companies and other procuring organisations acquire biotechnology-related products and services in a transparent, competitive, safe and accountable manner.

It covers procurement of:

Vaccines, biological medicines, diagnostic kits and laboratory reagents.

Genetically engineered organisms, biological samples and research materials.

Bioreactors, genome-sequencing equipment and laboratory instruments.

Biotechnology research services, clinical-trial services and contract manufacturing.

Agricultural biotechnology products, biofertilisers and genetically modified seeds.

Biological data systems, biobanking services and related intellectual property.

The subject combines public procurement law, administrative law, biosafety regulation, pharmaceutical regulation, competition law, contract law and public accountability.

In India, there is no single comprehensive statute exclusively governing all biotechnology procurement. The applicable framework depends on the procuring entity, the product, the funding arrangement and the risks involved. For central government procurement, the General Financial Rules (GFR), 2017, the applicable procurement manuals, constitutional principles and relevant sector-specific legislation form important parts of the framework.

Department of Expenditure+1

Important distinction: “Biotechnology Procurement Governance Accountability” is a useful analytical framework, not the name of a single established Indian statute or judicially recognised doctrine.

2. Meaning and scope of the three concepts

A. Procurement governance

Governance concerns how procurement decisions are planned, authorised, evaluated, documented and monitored. It requires clear tender conditions, objective evaluation criteria, appropriate technical expertise and proper contract management.

B. Procurement accountability

Accountability means that procurement officers, technical evaluators, institutional heads, suppliers and contractors can be required to justify their actions and answer for misconduct, negligence, regulatory breaches or contractual non-performance.

C. Biotechnology-specific oversight

Biotechnology procurement requires additional scrutiny of product quality, biological safety, traceability, storage conditions, contamination risks, regulatory approvals, ethical safeguards and the reliability of scientific evidence.

The central principle is that a procurement decision must be lawful, fair, scientifically justified, financially responsible and capable of independent review.

3. Legal framework in India

A. Constitutional provisions

Article 14 — Equality and non-arbitrariness

Government procurement must not be arbitrary, discriminatory or manipulated to favour a particular supplier. Tender criteria should be relevant to the actual technical and public-health requirements.

Article 19(1)(g) — Freedom of trade and business

Eligible suppliers have constitutional interests in participating in lawful commercial activity. This does not create an unconditional right to win a government contract, but procurement restrictions must comply with applicable constitutional standards.

Article 299 — Government contracts

Government contracts must comply with the constitutional requirements governing their execution by authorised persons.

Article 21 — Life and personal liberty

Article 21 may be relevant when procurement decisions affect access to essential healthcare, patient safety or environmental and public-health protection. Its application depends on the facts and the nature of the state action.

These provisions are especially important where a biotechnology tender affects access to essential medicines, public-health infrastructure or public research funding. The Government of India's Manual for Procurement of Goods, Second Edition, 2024 discusses the constitutional and administrative responsibilities associated with procurement.

Department of Expenditure+1

B. General Financial Rules and procurement manuals

The GFR, 2017, and the applicable Department of Expenditure procurement manuals establish financial and procedural expectations for covered government entities.

Relevant principles include:

Clear and proportionate technical specifications.

Fair competition and equal treatment of bidders.

Evaluation according to published criteria.

Assessment of price reasonableness and value for money.

Proper authorisation, documentation and audit trails.

Contract monitoring and responsibility for procurement outcomes.

Rule 149 addresses procurement through the Government e-Marketplace (GeM) for goods and services covered by its requirements. Other rules address tendering, procurement procedures, competition and related financial controls. Their precise application depends on the current rules and the category of purchase.

Department of Expenditure+1

C. Biotechnology and biosafety legislation

The procurement of biological materials is not merely a purchasing exercise. The purchaser must also determine whether acquisition, transport, storage, research use or release of the material is legally permitted.

Important legislation and regulatory instruments include:

The precise approval, licence, registration or notification required varies by product and activity. For example, a laboratory reagent, an investigational biological drug and a genetically engineered organism do not necessarily follow the same regulatory pathway.

IBKP+1

4. Core principles of procurement governance and accountability

4.1 Transparency and fair competition

A procuring authority should publish clear requirements, eligibility criteria, evaluation methods, deadlines and contract conditions. Confidential technical information must be protected, but confidentiality cannot be used to conceal favouritism or procedural irregularities.

For example, a government laboratory seeking a DNA sequencing platform should specify validated performance requirements, service support, data compatibility and warranty obligations rather than unnecessarily prescribing a proprietary brand that excludes equivalent products.

4.2 Scientific and technical accountability

Technical evaluation should be conducted by suitably qualified experts. Assessments should consider:

Product identity, purity and quality.

Required regulatory authorisations.

Validated performance and reproducibility.

Contamination control and storage requirements.

Batch traceability and recall procedures.

Suitability for the intended clinical or research purpose.

A product should not be accepted merely because it is inexpensive. Conversely, a supplier should not be rejected on subjective grounds unsupported by the tender or scientific evidence.

4.3 Financial accountability

Procurement officials should establish that the purchase is necessary, the price is reasonable, the funding is authorised and the supplier can fulfil the contract.

In biotechnology, lifecycle costs can be particularly important. The initial purchase price of a laboratory instrument may be low, but proprietary consumables, maintenance contracts, calibration, software licences and cold-chain logistics can substantially increase the total cost.

4.4 Biosafety and regulatory accountability

Before procuring regulated biological materials, an institution should verify the applicable permissions and safety requirements. Relevant controls may include authorised handling, transport documentation, suitable containment facilities, staff training and incident-reporting arrangements.

The Indian biosafety framework under the Environment (Protection) Act, 1986, and the Rules, 1989, assigns regulatory functions to designated authorities, including the Genetic Engineering Appraisal Committee (GEAC) and Review Committee on Genetic Manipulation (RCGM), according to their respective mandates.

IBKP+1

4.5 Ethical and data governance

Procurement of human biological samples, genomic testing, clinical-trial services or biobanking services may require additional safeguards concerning informed consent, privacy, lawful secondary use, sample transfer and research ethics.

Contractual confidentiality alone does not establish that a proposed use of human samples or genetic data is lawful. The applicable research, medical, data-protection and institutional requirements must be assessed independently.

4.6 Auditability and recordkeeping

A defensible procurement file should ordinarily contain:

The statement of need and approved budget.

Market research and the technical specification.

Tender publication and bidder communications.

Conflict-of-interest declarations.

Technical and financial evaluation records.

The reasons for selection, rejection or cancellation.

Contract, delivery, inspection and acceptance records.

Payment approvals, performance reports and audit findings.

These records allow the institution to demonstrate that its decisions were made for legitimate reasons rather than private benefit.

5. Important Indian case laws

The following decisions provide judicial principles relevant to biotechnology procurement. Some concern pharmaceutical or medical-product procurement directly; others establish general tender-law principles applicable by analogy. They should not be described as a separate body of case law exclusively on biotechnology procurement.

Case 1: Tata Cellular v. Union of India (1994)

Citation: (1994) 6 SCC 651 — Supreme Court of India

Facts and issue: The case concerned judicial review of government tendering and the limits of judicial intervention in administrative decisions.

Legal principle: Courts primarily examine the legality of the decision-making process rather than substituting their own commercial judgment for that of the tendering authority. Review may be appropriate where the decision is unlawful, irrational, procedurally improper or affected by relevant administrative-law defects.

Application to biotechnology procurement: A court would not ordinarily choose which vaccine supplier or laboratory instrument is commercially preferable. It may, however, examine whether a tender was manipulated, mandatory procedures were disregarded or bidders were treated arbitrarily.

Case 2: Jagdish Mandal v. State of Orissa (2007)

Citation: (2007) 14 SCC 517 — Supreme Court of India

Facts and issue: The case examined the circumstances in which courts should interfere with tender decisions and public contracts.

Legal principle: Judicial intervention is generally justified where the process is arbitrary, discriminatory, malicious or intended to favour someone, and where public interest warrants intervention. The court must distinguish a genuine public-interest challenge from a disappointed bidder's attempt to reopen a lawful commercial decision.

Application: If a biotechnology tender requires unnecessarily restrictive experience criteria that effectively predetermine the winner, judicial review may be available. A losing bidder's disagreement with a scientifically defensible evaluation, by itself, is not sufficient.

Case 3: Michigan Rubber (India) Ltd. v. State of Karnataka (2012)

Citation: (2012) 8 SCC 216 — Supreme Court of India

Legal principle: Government authorities generally enjoy discretion to determine tender eligibility conditions, subject to constitutional and administrative-law limits. Courts are cautious about interfering with conditions designed to ensure the contractor's capability and reliable performance.

Application: A requirement that a supplier demonstrate validated manufacturing capacity or a reliable cold-chain system may be legitimate for a sensitive biological product. An eligibility criterion that lacks a rational connection to the contract may be more vulnerable to challenge.

Case 4: Association of Registration Plates v. Union of India (2005)

Citation: (2005) 1 SCC 679 — Supreme Court of India

Legal principle: Tendering authorities can prescribe reasonable technical, financial and experience requirements to ensure reliable performance. Such conditions are not automatically unconstitutional merely because they restrict the number of eligible bidders.

Application: A tender for vaccine manufacturing or diagnostic kits may require appropriate quality certifications, proven manufacturing capability and sustainable delivery capacity. These requirements should be proportionate to the risk and nature of the procurement.

The above four decisions establish the general principles governing judicial review of public procurement. Their relevance lies in the legality and fairness of the procurement process, not in creating automatic liability whenever a bidder is excluded.

Orissa High Court+1

Case 5: Haffkine Bio-Pharmaceutical Corporation Ltd. v. Nirlac Chemicals (2017)

Supreme Court of India, judgment dated 27 July 2017

Facts: The dispute arose from a tender for bulk polio drugs issued by Haffkine Bio-Pharmaceutical Corporation. The tender process was challenged over procedural irregularities concerning the opening and evaluation of bids.

Decision and significance: The Supreme Court addressed the procedural defect in the tender process and the consequences for the award. The case illustrates that procurement authorities cannot disregard essential procedural safeguards simply because a preferred supplier appears commercially suitable.

Application to biotechnology procurement:

Bid-opening and evaluation procedures should be followed consistently.

Technical disqualification must be supported by the applicable tender conditions.

Procurement authorities should retain records demonstrating compliance.

Procedural irregularities can undermine the legitimacy of a public-health procurement.

This is particularly relevant when a government agency purchases vaccines, biological drugs or other essential medical products.

Free Law

Case 6: Lifecare Innovations Pvt. Ltd. v. Union of India (2025)

Citation: 2025 INSC 269 — Supreme Court of India, decided 25 February 2025

Particularly relevant

Facts: Lifecare Innovations, a micro enterprise manufacturing liposomal Amphotericin B, challenged barriers to participation in government procurement, including minimum-turnover conditions. The case also examined the enforceability of the Public Procurement Policy for Micro and Small Enterprises, 2012.

Key findings:

The Court held that the 2012 MSE Procurement Preference Order has the force of law.

Although an individual MSE does not possess an unconditional right to a particular minimum share of government procurement, the relevant authorities have enforceable duties to implement the policy.

Minimum-turnover clauses must be examined in light of the bidder's capacity and capability, the nature of the procurement and the applicable MSE policy.

The authorities were directed to examine implementation of the procurement target and formulate appropriate guidance concerning unreasonable turnover requirements.

Sci API+1

Importance for biotechnology procurement governance

This judgment is especially significant because it concerns a specialised medicine and demonstrates the relationship between public-health requirements, fair competition and accountability.

A procurement authority may legitimately require evidence that a manufacturer can supply a life-saving biological medicine safely and consistently. However, a blanket turnover threshold may be inappropriate if it excludes specialised manufacturers without adequately assessing their actual production capacity, product-specific experience or delivery capability.

The ruling does not prohibit all minimum-turnover conditions. Rather, it reinforces the need to reconcile legitimate procurement safeguards with applicable statutory procurement preferences.

Case 7: Maa Binda Express Carrier v. North-East Frontier Railway (2014)

Citation: (2014) 3 SCC 760 — Supreme Court of India

Legal principle: A person participating in a tender is entitled to fair and lawful consideration, but does not acquire an automatic right to have the contract awarded to them. The tendering authority retains discretion, subject to legal limits.

Application: A biotechnology supplier cannot demand an award merely because its product is innovative or its quoted price is the lowest. The supplier must satisfy the legitimate tender requirements, while the authority must exercise its discretion fairly and in accordance with law.

Orissa High Court

6. Accountability of different stakeholders

Accountability is not the same as automatic punishment. Liability depends on the applicable legal duty, evidence, the person's role and the relevant legal standard.

For example, a defective biological product may lead to different legal consequences for a manufacturer, a distributor and a procurement officer. The mere fact that the product failed does not establish that every participant acted negligently or unlawfully.

7. Common procurement violations and legal consequences

1. Tailored tender specifications

A tender is designed around a favoured supplier without a legitimate technical justification.

Possible response: Tender challenge, judicial review, cancellation or re-tendering where legally warranted.

2. Procurement of unapproved or unsuitable biological products

The purchaser fails to verify regulatory status, required quality evidence or permitted use.

Possible response: Rejection, quarantine, suspension of use, regulatory investigation and contractual remedies, depending on the circumstances.

3. Bid manipulation or collusion

Suppliers coordinate bids or officials improperly influence the award.

Possible response: Competition-law enforcement, vigilance proceedings, debarment under applicable rules or criminal proceedings if the evidence establishes an offence.

4. Inadequate cold-chain management

Vaccines or biological medicines are transported or stored outside the required conditions.

Possible response: Batch rejection, recall, corrective action and contractual or regulatory consequences.

5. Disproportionate financial eligibility criteria

A tender imposes a turnover requirement that unnecessarily excludes capable specialised or small manufacturers.

Possible response: Representation to the procuring authority, use of applicable grievance mechanisms or judicial review where legally justified.

8. A practical governance model for biotechnology procurement

An effective procurement system can be structured around six stages.

Needs assessment: Establish the public-health or research need, expected quantity, budget and technical specifications.

Regulatory screening: Determine the required licences, approvals, quality certifications and biosafety safeguards.

Fair tendering: Publish objective eligibility conditions and transparent evaluation criteria, subject to applicable procurement rules.

Independent evaluation: Separate technical assessment from financial evaluation where appropriate and document the reasons for decisions.

Contract performance: Verify delivery, product quality, storage conditions, traceability and agreed service levels.

Audit and remediation: Review expenditure and performance, investigate irregularities, address complaints and implement corrective action.

This model helps align scientific integrity with financial discipline and legal accountability.

9. International perspective

The same general principles are reflected in several international frameworks:

WTO Agreement on Government Procurement (GPA): Relevant to covered parties and procurements, subject to its scope and commitments; it is not a universal rule binding every Indian procurement.

UNCITRAL Model Law on Public Procurement: Provides a model for transparent procedures, competition and review mechanisms; it is not automatically binding domestic legislation.

Cartagena Protocol on Biosafety: Addresses the safe handling, transport and use of living modified organisms within its scope.

Convention on Biological Diversity and the Nagoya Protocol: Relevant to biodiversity conservation, access to genetic resources and benefit-sharing where applicable.

These instruments demonstrate that procurement governance may involve both ordinary purchasing rules and specialised safeguards for biological resources and environmental risks.

IBKP+1

10. Critical analysis

Three tensions are especially important.

First, innovation versus competition. Biotechnology markets may contain specialised suppliers whose products cannot be assessed solely through turnover or market share. Procurement rules must protect delivery reliability without unnecessarily excluding capable innovators.

Second, speed versus safety. Emergencies may justify accelerated purchasing under applicable rules, but they do not automatically eliminate legal authorisation, product-quality requirements or the need to document decisions.

Third, confidentiality versus accountability. Trade secrets and sensitive research information may deserve protection. Nevertheless, confidentiality should not prevent lawful scrutiny of spending, conflicts of interest, product safety or the reasons for awarding a contract.

The best approach is risk-based and evidence-driven. A purchase of ordinary laboratory consumables should not necessarily require the same controls as a purchase involving a high-risk biological agent or a critical injectable medicine.

11. Conclusion

Biotechnology Procurement Governance Accountability is best understood as the integration of fair procurement, scientific evaluation, biosafety compliance, financial control and institutional responsibility.

The Indian legal position can be summarised as follows:

Fairness: Article 14 constrains arbitrary and discriminatory government procurement.

Financial discipline: Applicable GFR provisions and procurement manuals govern covered government purchases.

Scientific safety: Relevant product-specific and biosafety legislation must be observed.

Judicial review: Courts can intervene in unlawful or arbitrary tender processes without routinely substituting their commercial judgment for that of procurement authorities.

Accountability: Officials and suppliers must comply with their respective legal and contractual duties.

Inclusive competition: Lifecare Innovations (2025) confirms that statutory MSE procurement obligations cannot simply be ignored when framing or applying tender conditions.

Ultimately, the objective is not merely to purchase biotechnology products at the lowest price. It is to obtain safe, effective, reliable and economically justified products through a transparent and legally defensible process.

For further study, the most useful next step would be to develop this framework into a case-law research paper with detailed judicial reasoning, relevant statutory provisions and a separate analysis of Indian Supreme Court decisions on pharmaceutical procurement and MSE tender eligibility.